Cancer Conversations™: PARP Inhibitors in Ovarian Cancer

Download All
Get up to date on the most recent developments in leveraging PARP inhibitors to optimally manage ovarian cancer with slides and an on-demand webcast capturing a dynamic Cancer Conversations webinar featuring expert discussion on key areas of consensus and controversy involving the latest data.
Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS
person default
Kathleen Moore, MD

Downloadable Slidesets

Download these slides from a live webinar to learn how to optimally manage ovarian cancer leveraging PARP inhibitors.

Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS person default Kathleen Moore, MD
Released: October 18, 2021

Download this summary slideset from a live webinar for a quick overview of the evolving use of PARP inhibitors for the management of ovarian cancer.

Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS person default Kathleen Moore, MD
Released: October 28, 2021

On-Demand Webcast

Watch this on-demand webcast of a live CCO webinar to hear a panel of experts discuss the current application of PARP inhibitors in ovarian cancer, including areas of consensus and the latest data informing open questions.

Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG, FACS person default Kathleen Moore, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: November 5, 2021 Expired: November 4, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue